Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China
The European Journal of Health Economics · 2024
DOI: 10.1007/s10198-024-01672-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift The European Journal of Health Economics, 2024. Verfasst von Aixue Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Fudan University, 130 Dong An Road, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Psychometrics, Quality of Life. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
AIM: To assess and compare the measurement properties of EQ-5D-5L and SF-6Dv2 among lymphoma patients in China. METHODS: A face-to-face survey of Chinese lymphoma patients was conducted at baseline (all types) and follow-up (diffuse large B-cell). EQ-5D-5L and SF-6Dv2 health utility scores (HUSs) were calculated using the respective Chinese value sets. Ceiling effect was assessed by calculating the percentage of respondents reporting the optimal health state. Convergent validity of EQ-5D-5L and SF-6Dv2 was assessed using the Spearman rank correlation coefficient (r) with QLQ-C30 as a calibration standard. Known-groups validity of the two HUSs was evaluated by comparing their scores of patients with different conditions; and their sensitivity was further assessed in the known-groups using relative efficiency (RE). Test-retest reliability and responsiveness was tested using ICC and standardized response mean (SRM), respectively. RESULTS: Altogether 200 patients were enrolled at baseline and 78 were followed up. No ceiling effect was found for SF-6Dv2 compared to 24.5% for EQ-5D-5L. Correlation between the two HUSs and with QLQ-C30 score was strong (r > 0.5). Each dimension of EQ-5D-5L and SF-6Dv2 had moderate or greater correlations with similar dimensions of QLQ-C30 (r > 0.35). Both EQ-5D-5L and SF-6Dv2 could only a minority known-groups, and the latter may have better sensitivity. EQ-5D-5L had better test-retest reliability (ICC = 0.939); while both of them were responsive to patients with worsened and improved clinical status. CONCLUSIONS: EQ-5D-5L and SF-6Dv2 were found to have good convergent validity and responsiveness, while EQ-5D-5L had better test-retest reliability and higher ceiling effect. Not enough evidence indicates which of the two measures has better known-group validity and sensitivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Public Health, Fudan University, 130 Dong An Road, Shanghai, 200032, China.
- Key Lab of Health Technology Assessment, National Health Commission of the People's Republic of China (Fudan University), Shanghai, China.
- Department of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.
- Centre for Health Economics Research and Modelling Infectious Diseases (CHER-MID), University of Antwerp, Antwerp, Belgium.
- School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhang, A., Li, J., Mao, Z., Wang, Z., Wu, J., Luo, N., Liu, P., & Wang, P. (2024). Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China. The European Journal of Health Economics. https://doi.org/10.1007/s10198-024-01672-4
Vancouver
Zhang A, Li J, Mao Z, Wang Z, Wu J, Luo N, et al. Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China. The European Journal of Health Economics. 2024. doi:10.1007/s10198-024-01672-4
BibTeX
@article{Zhang2024,
author = {Zhang, Aixue and Li, Jing and Mao, Zhuxin and Wang, Zitong and Wu, Jing and Luo, Nan and Liu, Peng and Wang, Pei},
title = {Psychometric performance of EQ-5D-5L and SF-6Dv2 in patients with lymphoma in China},
journal = {The European Journal of Health Economics},
year = {2024},
doi = {10.1007/s10198-024-01672-4}
}
EUVIMED